TY - JOUR
T1 - Characterization and application of two RANK-specific antibodies with different biological activities
AU - Chypre, Mélanie
AU - Seaman, Jonathan
AU - Cordeiro, Olga G.
AU - Willen, Laure
AU - Knoop, Kathryn A.
AU - Buchanan, Andrew
AU - Sainson, Richard C.A.
AU - Williams, Ifor R.
AU - Yagita, Hideo
AU - Schneider, Pascal
AU - Mueller, Christopher G.
N1 - Funding Information:
We thank Dominique Heymann (INSERM UMR-S 957, Université de Nantes) for HEK 293 hRANK cells, Olivier Chaloin for help in surface plasmon resonance measurements, the MedImmune Biologics Expression team for antibody expression and purification, and members of the Strasbourg laboratory for help and discussion. CGM was supported by FP7-MC-ITN 289720 “Stroma”, a convention between Prestwick Chemical and Centre National pour la Recherche Scientifique, Institut National du Cancer (2012-107), Institut National du Cancer N° 2012-107 and l’Agence Nationale pour la Recherche (Program “Investissements d’Avenir”, ANR-10-LABX-0034 MEDALIS; ANR-11-EQPX-022). PS is supported by grants from the Swiss National Science Foundation .
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Antibodies play an important role in therapy and investigative biomedical research. The TNF-family member Receptor Activator of NF-κB (RANK) is known for its role in bone homeostasis and is increasingly recognized as a central player in immune regulation and epithelial cell activation. However, the study of RANK biology has been hampered by missing or insufficient characterization of high affinity tools that recognize RANK. Here, we present a careful description and comparison of two antibodies, RANK-02 obtained by phage display (Newa, 2014 [1]) and R12-31 generated by immunization (Kamijo, 2006 [2]). We found that both antibodies recognized mouse RANK with high affinity, while RANK-02 and R12-31 recognized human RANK with high and lower affinities, respectively. Using a cell apoptosis assay based on stimulation of a RANK:Fas fusion protein, and a cellular NF-κB signaling assay, we showed that R12-31 was agonist for both species. R12-31 interfered little or not at all with the binding of RANKL to RANK, in contrast to RANK-02 that efficiently prevented this interaction. Depending on the assay and species, RANK-02 was either a weak agonist or a partial antagonist of RANK. Both antibodies recognized human Langerhans cells, previously shown to express RANK, while dermal dendritic cells were poorly labeled. In vivo R12-31 agonist activity was demonstrated by its ability to induce the formation of intestinal villous microfold cells in mice. This characterization of two monoclonal antibodies should now allow better evaluation of their application as therapeutic reagents and investigative tools.
AB - Antibodies play an important role in therapy and investigative biomedical research. The TNF-family member Receptor Activator of NF-κB (RANK) is known for its role in bone homeostasis and is increasingly recognized as a central player in immune regulation and epithelial cell activation. However, the study of RANK biology has been hampered by missing or insufficient characterization of high affinity tools that recognize RANK. Here, we present a careful description and comparison of two antibodies, RANK-02 obtained by phage display (Newa, 2014 [1]) and R12-31 generated by immunization (Kamijo, 2006 [2]). We found that both antibodies recognized mouse RANK with high affinity, while RANK-02 and R12-31 recognized human RANK with high and lower affinities, respectively. Using a cell apoptosis assay based on stimulation of a RANK:Fas fusion protein, and a cellular NF-κB signaling assay, we showed that R12-31 was agonist for both species. R12-31 interfered little or not at all with the binding of RANKL to RANK, in contrast to RANK-02 that efficiently prevented this interaction. Depending on the assay and species, RANK-02 was either a weak agonist or a partial antagonist of RANK. Both antibodies recognized human Langerhans cells, previously shown to express RANK, while dermal dendritic cells were poorly labeled. In vivo R12-31 agonist activity was demonstrated by its ability to induce the formation of intestinal villous microfold cells in mice. This characterization of two monoclonal antibodies should now allow better evaluation of their application as therapeutic reagents and investigative tools.
KW - Epithelial microfold cell
KW - Langerhans cell
KW - Monoclonal antibody
KW - RANK (TNFRSF11a)
UR - http://www.scopus.com/inward/record.url?scp=84954321159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954321159&partnerID=8YFLogxK
U2 - 10.1016/j.imlet.2016.01.003
DO - 10.1016/j.imlet.2016.01.003
M3 - Article
C2 - 26773232
AN - SCOPUS:84954321159
SN - 0165-2478
VL - 171
SP - 5
EP - 14
JO - Immunology Letters
JF - Immunology Letters
ER -